The country dossiers

Eleven European subjects, each set out the same way: key facts with dates, background, what the documents say, the positions of the parties, this site's reading marked as interpretation, and the questions still open. Sources are linked at the end of each dossier, in the original language where that is the only version.

The Dutch protocol: origins and follow-up data

Where did puberty blockers for adolescents come from, and what did the Amsterdam follow-up studies actually show?

Puberty blockers did not originate as a treatment for adolescent gender distress. Gonadotrophin-releasing hormone agonists, usually abbreviated to GnRH agonists or GnRHa, were already used in paediatric endocrinology to suppress unusually early puberty, and in other branches of medicine for hormone-sensitive conditions. The Dutch innovation was to apply these drugs to adolescents diagnosed with gender identity disorder, later termed gender dysphoria, as part of a staged pathway towards medical transition.

Sweden: Karolinska, SBU and the 2022 guidelines

Why did Sweden's Karolinska hospital stop hormonal treatment of minors in 2021 and what did the national board decide in 2022?

Sweden’s change was not the result of a new Act of Parliament banning medical transition for minors. It was a sequence of clinical and national evidence-policy decisions. The first was local: Astrid Lindgren Children’s Hospital, part of Karolinska University Hospital in Stockholm, altered its practice in spring 2021. The second was national: Socialstyrelsen, Sweden’s National Board of Health and Welfare, revised its recommendations for under-18s in 2022 after commissioning an evidence review from SBU, the Swedish Agency for Health Technology Assessment and Assessment of Social Services.

Finland: COHERE and the 2020 recommendation

What did Finland's Council for Choices in Health Care conclude in 2020, and how did Finnish practice change?

Finland’s Council for Choices in Health Care, known in Finnish as PALKO and in English as COHERE Finland, operates in connection with the Ministry of Social Affairs and Health. Its role is to recommend which treatments belong within publicly funded healthcare. Its recommendation, Medical treatment methods for dysphoria associated with variations in gender identity in minors , was adopted on 11 June 2020 and published in summary form five days later (COHERE Finland, 2020).

Norway: the UKOM report and the 2023 warning

What did Norway's healthcare investigation board find about the evidence for treating minors, and what followed?

Norway’s 2023 intervention in the debate over medical transition for minors came not from a political party or a campaigning organisation, but from Ukom, the Norwegian Healthcare Investigation Board. Ukom is an independent public body established under the Act of 16 June 2017 on the Norwegian Healthcare Investigation Board. Its task is to investigate serious incidents and serious conditions in health and care services in order to improve patient safety through learning and prevention; it does not decide criminal or civil liability (Act on the Norwegian Healthcare Investigation Board, 2017).

Germany: the S2k guideline and the self-determination law

How does Germany's 2024 guideline on gender incongruence in minors compare with the Nordic reviews, and what did the self-determination law change?

Germany’s position is frequently presented as a direct answer to the Nordic reappraisals of paediatric gender medicine. That is only partly accurate. Germany has two distinct policy tracks: a clinical guideline for assessment and treatment, and a civil-status law on the legal recording of sex and names. The two are politically connected in public debate, but legally separate.

France: the Académie de Médecine and the Senate report

What did the French Academy of Medicine warn in 2022, and what did the 2024 Senate report recommend?

France’s debate on medical pathways for gender-distressed minors has often been described as a dispute between “affirmative” care and a more exploratory clinical approach. The national record is more complicated than that shorthand suggests. France has had specialist hospital consultations, but no final, nationwide clinical guideline specifically governing the care of minors. The Haute Autorité de santé (HAS), France’s independent health authority, began a new minors’ guidance project in May 2026. This is important: neither a political report nor a parliamentary vote is a substitute for a clin

The Netherlands: Amsterdam UMC and the Dutch reassessment

How has the Netherlands responded to criticism of its own protocol, and what has the Dutch health ministry decided?

The Netherlands matters because the “Dutch protocol” became the best-known model for paediatric medical transition internationally. It was developed at the Amsterdam gender clinic, formerly VUmc and now Amsterdam UMC, around a highly selected group of adolescents with persistent gender dysphoria, intensive assessment and family support. The model combined psychological assessment, puberty suppression after the onset of puberty, cross-sex hormones in later adolescence, and, historically, surgery in adulthood.

Detransition in Europe: studies and registries

What do European registries and studies show about detransition and regret?

“Detransition” is not a single measurable outcome. It can mean stopping puberty blockers or cross-sex hormones, reversing a legal sex marker, changing one’s name or presentation, seeking reconstructive or reversal treatment, or simply coming to regret an earlier medical decision. These are related but different events. A patient may cease hormones because of adverse effects, cost, fertility plans, health concerns, dissatisfaction, a changed identity, inadequate follow-up, or a temporary interruption; discontinuation is therefore not automatically proof of regret. Equally, recorded regret is no

Denmark, Iceland and the Nordic debates

How have Denmark and Iceland handled youth gender medicine, women's sport and single-sex spaces?

Denmark and Iceland are often grouped with the Nordic countries as socially liberal states with strong legal protections for LGBT people. Both have separated legal gender recognition from medical transition. Neither country, however, has produced the kind of national reversal in paediatric gender medicine seen in Finland, Sweden and, to a lesser extent, Norway. This matters because legal recognition, clinical treatment, women’s sport and changing facilities are related politically but are governed through different laws and institutions.

Spain's ley trans and the Spanish debate

What did Spain's 2023 trans law introduce, and how has the Spanish debate on self-identification and speech developed?

Spain’s 2023 “Ley Trans” is formally Ley 4/2023, de 28 de febrero, para la igualdad real y efectiva de las personas trans y para la garantía de los derechos de las personas LGTBI . It is a wide-ranging statute: alongside changes to legal sex registration, it covers employment, education, healthcare, media, sport, family law, discrimination and administrative sanctions. Its best-known provision is the move to legal sex self-identification.

The European Court of Human Rights and gender identity

What has the Strasbourg court ruled on legal gender recognition, and how far does it bind member states?

The European Court of Human Rights in Strasbourg has developed a significant body of case-law on legal gender recognition. Its rulings are often invoked in political debate as if they required every Council of Europe state to adopt self-declaration systems or to treat legal sex as irrelevant in all areas of law. That is not what the judgments say. The Court has recognised a protected private-life interest in legal recognition for transgender people, prohibited compulsory sterilisation as a condition of recognition, and required workable procedures. It has also repeatedly left substantial quest